ATE322016T1 - Screeningsverfahren zur änderung zirkadiane- rhythmus-eiweisse - Google Patents

Screeningsverfahren zur änderung zirkadiane- rhythmus-eiweisse

Info

Publication number
ATE322016T1
ATE322016T1 AT00939629T AT00939629T ATE322016T1 AT E322016 T1 ATE322016 T1 AT E322016T1 AT 00939629 T AT00939629 T AT 00939629T AT 00939629 T AT00939629 T AT 00939629T AT E322016 T1 ATE322016 T1 AT E322016T1
Authority
AT
Austria
Prior art keywords
alter
ability
directed
phosphorylation
circadian rhythm
Prior art date
Application number
AT00939629T
Other languages
English (en)
Inventor
George Keesler
Cesare Mondadori
Zhengbin Yao
Fernando Camacho
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE322016T1 publication Critical patent/ATE322016T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrophonic Musical Instruments (AREA)
  • Peptides Or Proteins (AREA)
AT00939629T 1999-06-08 2000-06-07 Screeningsverfahren zur änderung zirkadiane- rhythmus-eiweisse ATE322016T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32774599A 1999-06-08 1999-06-08

Publications (1)

Publication Number Publication Date
ATE322016T1 true ATE322016T1 (de) 2006-04-15

Family

ID=23277866

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00939629T ATE322016T1 (de) 1999-06-08 2000-06-07 Screeningsverfahren zur änderung zirkadiane- rhythmus-eiweisse

Country Status (15)

Country Link
US (1) US6555328B1 (de)
EP (1) EP1183541B1 (de)
JP (1) JP4583682B2 (de)
KR (1) KR100722176B1 (de)
AT (1) ATE322016T1 (de)
AU (1) AU767800B2 (de)
BR (1) BR0011437A (de)
CA (1) CA2375450C (de)
DE (1) DE60026998T2 (de)
IL (2) IL146729A0 (de)
MX (1) MXPA01011417A (de)
NO (3) NO330241B1 (de)
NZ (1) NZ514603A (de)
WO (1) WO2000075669A1 (de)
ZA (1) ZA200108962B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476188B1 (en) 1998-06-19 2002-11-05 The Rockefeller University Clock gene and methods of use thereof
US6436628B1 (en) 1998-06-19 2002-08-20 The Rockefeller University Methods of identifying an agent which modulates period and doubletime protein interaction
ATE322016T1 (de) * 1999-06-08 2006-04-15 Aventis Pharma Inc Screeningsverfahren zur änderung zirkadiane- rhythmus-eiweisse
EP1235915B1 (de) * 1999-11-18 2009-05-27 Mitsubishi Tanabe Pharma Corporation Transgene säugetiere mit einem period 1 promotor, der rhythmische expression verleiht
GB0103110D0 (en) * 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
AU2002248338A1 (en) * 2001-01-11 2002-07-24 University Of Utah Research Foundation Identification of an advanced sleep phase syndrome gene in humans
WO2004038043A2 (en) * 2002-10-25 2004-05-06 University Of Surrey POLYMORPHISM IN THE Per3 GENE AS A INDICATOR IN THE DIAGNOSIS AND TREATMENT OF CIRCADIAN RHYTHM SLEEP DISORDERS
US20060134619A1 (en) * 2002-11-27 2006-06-22 Louis Ptacek Casein kinase i epsilon and casein kinase i delta and sleep in humans
ATE445396T1 (de) * 2004-08-19 2009-10-15 Aventis Pharma Inc 3-arylthioindol-2-carbonsäureamidderivate und ihre analoge als hemmer von caseinkinase i
JO2629B1 (en) 2004-08-19 2012-06-24 افينتيس فارما سوتيكالز انك Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon
JO2724B1 (en) * 2004-08-19 2013-09-15 افينتس فارماسوتيكالز انك 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors
US20100028871A1 (en) * 2006-05-31 2010-02-04 National Institute Of Radiological Sciences Light-inducible and rhythmically expressed genes and method for screening substances that affect an internal clock system
ES2425179T3 (es) * 2006-10-25 2013-10-11 The Rockefeller University Métodos para el tratamiento de trastornos relacionados con beta-amiloide y composiciones para los mismos
FR2918986B1 (fr) 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
CN105744948B (zh) * 2013-10-14 2020-03-24 南京大学 进食节律提前综合征的识别方法及其应用
KR101600144B1 (ko) 2013-12-20 2016-03-04 서울대학교산학협력단 일주기 리듬 수면장애 및 시차 부적응에 대한 예방 또는 치료제 스크리닝 방법
ES2728932T3 (es) 2014-01-09 2019-10-29 Intra Cellular Therapies Inc Compuestos orgánicos
WO2017083835A1 (en) * 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York Inhibition of tor complex 2 increases immunity against bacterial infection
WO2023129377A1 (en) * 2022-01-03 2023-07-06 The Johns Hopkins University Methods and materials for treating heart attack

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1157137A (ja) * 1997-08-28 1999-03-02 Sanyo Bussan Kk 遊技機用特別図柄表示装置
KR100246893B1 (ko) * 1997-12-29 2000-05-01 윤종용 전자렌지용 도어
AU3976099A (en) * 1998-05-07 1999-11-23 President & Fellows Of Harvard College, The Compositions and methods involving regulation of mammalian circadian rhythms
ATE322016T1 (de) * 1999-06-08 2006-04-15 Aventis Pharma Inc Screeningsverfahren zur änderung zirkadiane- rhythmus-eiweisse

Also Published As

Publication number Publication date
KR20020033101A (ko) 2002-05-04
NO20015972L (no) 2002-02-05
WO2000075669A1 (en) 2000-12-14
ZA200108962B (en) 2003-01-30
JP2003501074A (ja) 2003-01-14
EP1183541B1 (de) 2006-03-29
EP1183541A1 (de) 2002-03-06
AU767800B2 (en) 2003-11-27
NO20015972D0 (no) 2001-12-06
KR100722176B1 (ko) 2007-05-29
DE60026998D1 (de) 2006-05-18
CA2375450A1 (en) 2000-12-14
NO330241B1 (no) 2011-03-14
NZ514603A (en) 2003-10-31
AU5468900A (en) 2000-12-28
US6555328B1 (en) 2003-04-29
JP4583682B2 (ja) 2010-11-17
IL146729A0 (en) 2002-07-25
NO20100431L (no) 2002-02-05
CA2375450C (en) 2009-04-28
BR0011437A (pt) 2002-03-05
DE60026998T2 (de) 2007-04-05
MXPA01011417A (es) 2002-06-04
IL146729A (en) 2007-06-17
NO20100430L (no) 2002-02-05

Similar Documents

Publication Publication Date Title
ATE322016T1 (de) Screeningsverfahren zur änderung zirkadiane- rhythmus-eiweisse
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69938662D1 (de) Spurendetektion von analyten mit hilfe artifizieller olfaktometrie
DE60323300D1 (de) Apparat zur Früherkennung von ischämischen Herzerkrankungen
DE69918549D1 (de) Gerät zur feststellung von zahnbelag mittels fluoreszenzmessung
DE69836915D1 (de) Mundpflegemittel zur behandlung von übelriechendem atem
DE60336298D1 (de) Medizinische implantierbare vorrichtung zur verminderung der effekten von magnetresonanz
ATE522623T1 (de) Zusammensetzungen und verfahren zur behandlung und diagnose von lungentumoren
DE69821667D1 (de) Kardioverter zur Behandlung von Vorhofflattern
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
DE59705007D1 (de) Elektrolyseapparat zur herstellung von halogengasen
EP1180040A4 (de) Methoden zur behandlung von kongestivem herzversagen
DE60320362D1 (de) Verfahren zur Herstellung von Dipeptiden
DE60104810D1 (de) Zellfreies Verfahren zur Herstellung von posttranslational veränderten Proteinen
DE69739026D1 (de) Nitril-Hydratase, ihre Derivate und Verfahren zur Herstellung von Verbindungen
DE69932845D1 (de) Methoden zur quantifizierung von hla-dr und cd11b
ATE218857T1 (de) Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE69326018D1 (de) Methoden zur bestimmung der blutplaettchenfunktion
DE60329000D1 (de) C-terminale globulardomäne von adiponectin zur behandlung von arteriosklerose
DE50212649D1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
ATE300944T1 (de) Verwendung von substituierten distamycin- acryloylderivaten zur behandlung von tumoren die mit erhöhten glutathion-spiegeln zusammenhängen
DE60200713D1 (de) Zusammensetzung enthaltend getrocknetes Vollei zur Behandlung von Hepatitis
DE69734890D1 (de) Rdgb-proteine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1183541

Country of ref document: EP

EEIH Change in the person of patent owner